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Abstract
Objective: To evaluate the clinical impact of an antimicrobial stewardship program (ASP) on high-risk pediatric patients.
Design: Retrospective cohort study.
Setting: Free-standing pediatric hospital.
Patients: This study included patients who received an ASP review between March 3, 2008, and March 2, 2017, and were considered high-risk,
including patients receiving care by the neonatal intensive care (NICU), hematology/oncology (H/O), or pediatric intensive care (PICU)
medical teams.
Methods: The ASP recommendations included stopping antibiotics; modifying antibiotic type, dose, or duration; or obtaining an infectious
diseases consultation. The outcomes evaluated in all high-risk patients with ASP recommendations were (1) hospital-acquired Clostridium
difficile infection, (2) mortality, and (3) 30-day readmission. Subanalyses were conducted to evaluate hospital length of stay (LOS) and
tracheitis treatment failure. Multivariable generalized linear models were performed to examine the relationship between ASP recommendations and each outcome after adjusting for clinical service and indication for treatment.
Results: The ASP made 2,088 recommendations, and 50% of these recommendations were to stop antibiotics. Recommendation agreement
occurred in 70% of these cases. Agreement with an ASP recommendation was not associated with higher odds of mortality or hospital
readmission. Patients with a single ASP review and agreed upon recommendation had a shorter median LOS (10.2 days vs 13.2 days;
P < .05). The ASP recommendations were not associated with high rates of tracheitis treatment failure.
Conclusions: ASP recommendations do not result in worse clinical outcomes among high-risk pediatric patients. Most ASP recommendations
are to stop or to narrow antimicrobial therapy. Further work is needed to enhance stewardship efforts in high-risk pediatric patients.
(Received 5 April 2019; accepted 19 June 2019; electronically published 17 July 2019)

Antimicrobial stewardship programs (ASPs) are an increasingly
prevalent service in hospitals; they aim to assure optimal antimicrobial prescribing. A critical component of an ASP is measuring
the impact of ASP interventions on antibiotic use and clinical
outcomes. Determining the impact of an ASP involves documenting process measures by which an ASP intervention directly
results in a medication change (eg, a decrease in antibiotics).
Outcome measures including hospital length of stay (LOS),
30-day mortality, hospital-acquired Clostridioides difficile
infection (HA-CDI), and infection treatment failure are reflective of overall patient care that can be impacted by ASP
recommendations.1
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The Infectious Diseases Society of America/Society for
Healthcare Epidemiology of America stewardship guidelines
emphasize the importance of assessing outcomes in specific
populations to better understand the clinical impact.1
Integrating an ASP into the care of high-risk patients in the
intensive care units (ICUs) and oncology wards is imperative
because antimicrobial use in these units is high, as are the unintended consequences of antimicrobials including multidrugresistant infections and HA-CDI.2–4 However, concerns about
unintended consequences of narrowing or discontinuing antimicrobial therapy in these critically ill patients can limit stewardship efforts.5–7
Despite the growing number of pediatric ASPs, 8 data on the
impact of ASPs on pediatric clinical outcomes are scarce, especially for high-risk children in ICUs or oncology wards.9,10
Thus, we sought to determine the clinical impact of our wellestablished prospective-audit-with-feedback ASP at a freestanding children’s hospital on these high-risk pediatric
patients.11,12
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Table 1. Antimicrobial Stewardship Program Monitored Antimicrobials

Study setting
Children’s Mercy Kansas City is a 354-bed free-standing, nonprofit, academic, pediatric medical center that provides comprehensive primary and tertiary care in 40 pediatric subspecialties
for a 5-state, 100-county region. The center has ~15,000 admissions annually. On March 3, 2008, a prospective-audit-withfeedback ASP was implemented that focused on improving
appropriateness of antibiotic use in children who had received a
broad-spectrum antibiotic for 2 consecutive calendar days. The
program was led by an infectious diseases physician and 2 infectious diseases clinical pharmacy specialists, who reviewed clinical
data and provided recommendations to the primary medical team.
ASP recommendations were broadly categorized into 4 areas: (1)
stopping antibiotic therapy, (2) modifying the antibiotic type, (3)
modifying the antibiotic dosage and/or duration, and (4) obtaining
an infectious diseases consultation. An ASP review was triggered
only if the patient was receiving an ASP-monitored antimicrobial
for 2 calendar days (Table 1).

Sample population and data sources
For this retrospective cohort study, patients who received an ASP
review between March 3, 2008, and March 2, 2017, and were considered high risk were eligible. High-risk patients included those
receiving care from the medical teams in the neonatal ICU
(NICU), the hematology/oncology ward (H/O), or the pediatric
ICU (PICU). High-risk patients could be reviewed by the ASP
team more than once during their hospital admission. For this
study, all ASP reviews that occurred for a high-risk patient were
included. Patients aged >17 years were excluded. Data for these
high-risk patients were extracted from our ASP repository,
including antibiotic(s) prescribed, antibiotic indication, dose of
antibiotic(s), length of therapy, and recommendations made by
the ASP. For ASP reviews resulting in a recommendation, provider agreement or disagreement with the recommendation
was documented.11,13,14
Additional clinical characteristics were abstracted from the
electronic medical record (EMR) and the pediatric health information system (PHIS) database. EMR data included select clinical and
demographic characteristics such as patient age, race/ethnicity,
gender, discharge diagnosis codes, all medication administrations,
Clostridioides difficile (C. difficile) testing, and mortality. The
classification of complex chronic care conditions, medical service
line, and 30-day readmission were based on data from the PHIS.
The PHIS is an administrative database that contains patient-level
billing data from >50 nonprofit, tertiary-care, pediatric hospitals in
the United States. These hospitals, including Children’s Mercy
Kansas City, are affiliated with the Children’s Hospital
Association (Mission, KS). Data quality and reliability are assured
through a joint effort between the Children’s Hospital Association
and participating hospitals. The data warehouse function for the
PHIS database is managed by Truven Health Analytics
(Ann Arbor, MI). Data are deidentified at the time of data submission and data are subjected to a number of reliability and validity
checks before being included in the database. Using internal
patient identifiers, the ASP repository and EMR data were merged
with the data obtained from the PHIS. This study was reviewed
and approved by Children’s Mercy Hospital’s Institutional
Review Board.

Amikacina

CeftolozaneTazobactama

Linezolida

Amoxicillin/
Clavulanate

Ceftriaxone

Meropenem

Ampicillin/Sulbactam

Ciprofloxacin

Aztreonam

Colistimethate

Cefepime

Daptomycina

Cefotaxime
Ceftaroline

a

Ceftazidime
a

Moxifloxacina
a

Piperacillin/
Tazobactam
Tigecyclinea

Ertapenem

Tobramycin
a

Imipenem/cilastatin

Vancomycin

Levofloxacina

Requires preauthorization.

Primary outcomes
Three primary outcomes were evaluated among all patients in this
study: HA-CDI, all-cause mortality during the patients’ current
hospitalization, and 30-day readmission. Cases of HA-CDI were
defined as having a positive stool sample (ie, positive GDH and
toxin antigen screen or if only GDH was positive, then confirmatory positive toxin PCR) and the patient was treated for HA-CDI
(ie, metronidazole, per-oral vancomycin, or fidaxomicin) within 24
hours of a positive result. Testing that occurred within the first 48
hours of admission were excluded to help ensure that only HACDIs were identified. Readmission was defined as all-cause 30day readmission, which implies that there was no restriction on
the underlying reason for the readmission.
Secondary outcomes
Two secondary outcomes were evaluated on a subset of the high-risk
cohort: hospital length of stay (LOS) and treatment failure among
high-risk patients diagnosed with ventilator-associated tracheitis
(VAT). The comparison of LOS was restricted to patients with a single ASP review because the relationship between LOS and ASP
review characteristics (eg, any recommendations, agreement with
recommendations, etc) was difficult to attribute when >1 ASP
review had been completed. The diagnosis of VAT was specifically
evaluated for the following reasons: (1) VAT is a commonly encountered and reviewed antibiotic indication in this high-risk population; (2) frequent recommendations are made by our ASP team
in regard to the treatment of VAT; and (3) the recommended treatment for VAT is either no antibiotics or a short course of antibiotics
(5 days). Only children reviewed by the ASP because they were
receiving an antibiotic(s) prescribed for VAT were included.
Children receiving antibiotics for concurrent indications (eg, pneumonia, bacteremia, or urinary tract infection) were excluded from
this subset. VAT treatment failure was defined as initiating a course
of antibiotics for the indication of VAT within 14 days following the
completion of the initial VAT treatment course. The LOS was
defined as the number of hours between the patients’ admission
and discharge from the hospital, converted to days.
Statistical analysis
All outcomes, with the exception of LOS, were modeled as binary.
The frequency distribution of these outcomes were compared across
clinical service categories, complex chronic condition (CCC) status,
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indication for treatment, by ASP recommendation type (eg, recommended conversion from intravenous to oral administration, stop
recommendation, etc), and combining all recommendations into
an “any recommendation” category. The frequency of the outcomes
was also compared based on whether the provider agreed with
recommendations. For the bivariate analysis unadjusted proportions and Fisher exact P values are reported. Comparisons of
LOS were performed using the Mann-Whitney U test.
Multivariable generalized linear models were performed to
examine the relationship between ASP recommendations and each
outcome after adjusting for clinical service and indication for treatment. Because all ASP reviews and outcomes had a known date/
time, the data were structured in a multiple time-to-event format.
The outcome was assumed to not have occurred if either (1) the
patient had subsequent ASP review or (2) the patient had been
discharged. Similar analytic approaches have frequently been used
to examine how modified exposures may affect outcomes that can
occur more than once.15–17 The patient identifier was used to
specify the R-side random effect, and the compound-symmetry
covariance matrix was employed. List-wise deletion was performed
for instances in which data were missing. All analyses were completed using SAS version 9.4 software (SAS Institute, Cary, NC).
Results
ASP reviews and recommendations
In total, 11,804 ASP reviews among high-risk patients were identified,
representing 7,414 unique encounters. Reviews of high-risk patients
accounted for 42.7% of all ASP reviews performed during the study
period. Also, 259 reviews of high-risk patients were excluded due to
incomplete data, resulting in a final analytic sample of 11,545 ASP
reviews (7,329 encounters). The high-risk patients had a median
age of 3.4 years (interquartile range, 0.2–9.4 years), 12% were of
Hispanic ethnicity, 16% were African American, 55% were male,
and 90.4% were classified as having a complex chronic condition.
The ASP reviews among H/O patients were most common
(46.6%), followed by patients in the PICU (27.6%) and the
NICU (25.8%) (Table 2). The most frequently reviewed drugs were
cefepime (29.1%), vancomycin (26.1%), and ceftriaxone (11.0%).
The most frequent indications for antimicrobial use were
suspected sepsis (23%) and fever with neutropenia (19.1%).
Overall, the ASP team provided recommendations on 2,088
reviews of high-risk patients (18.1%). A trend analysis showed that
the likelihood of receiving a recommendation during the study time
period remained stable. These recommendations were made in
1,768 unique patients who received 1 or more ASP recommendations. The most frequent recommendation was to stop therapy
(50.1%). Overall, provider disagreement with ASP recommendations occurred in 31% of cases. Disagreement was defined as follows:
at the time of an ASP recommendation, the medical team did not
agree or agreed but did not adhere to the ASP recommendation.
Disagreement with ASP most commonly occurred when the recommendation was to stop an antimicrobial (Fig. 1). A significant
increase in disagreement with an ASP recommendation was
observed during the study period from 29.6% to 41.0% (P = .001).
Primary outcomes
In total, 356 patients (4.8%) who underwent at least 1 ASP review
died during their hospitalization (Table 3). In patients for whom an
ASP recommendation was given, the odds of mortality was significantly lower (adjusted odds ratio [aOR], 0.72; 95% confidence
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Table 2. Clinical Characteristics of High-Risk ASP Reviews
Characteristic

No.(N=11,545)

%

Hematology/Oncology

5,093

46.6

PICU

3,018

27.6

NICU

2,824

25.8

Cefepime

3,355

29.1

Vancomycin

3,016

26.1

Ceftriaxone

1,272

11.0

Cefotaxime

1,235

10.7

Meropenem

1,084

9.4

Suspected sepsis

2,648

23.0

Fever/Neutropenia

2,196

19.1

Bloodstream infection

1,345

11.7

Respiratory (non-CAP) infection

724

6.3

ENT disorder

653

5.7

Any ASP recommendation

2,088

18.1

Stop therapy

1,045

9.1

474

4.1

ID consultation

334

2.9

Optimize

237

2.1

Patient ward

Top 5 reviewed antibiotics

Top 5 indications for treatment

ASP Recommendation

Narrow therapy

IV:PO conversion
Agreed with recommendationsa

71

0.6

1,360

69.9

Note. PICU, pediatric intensive care unit; NICU, neonatal intensive care unit; CAP, communityacquired pneumonia, ENT, ear, nose, and throat; ASP, antimicrobial stewardship program;
ID, infectious diseases; IV:PO, intravenous to oral drug administration.
a
Among those with ASP recommendations.

interval [CI], 0.54–0.96; P = .023) (Table 3). Overall, readmissions
occurred in 2,608 high-risk patients (23.3%) reviewed by ASP. A
stop recommendation was not associated with increased odds of
30-day readmission (aOR, 0.98; 95% CI, 0.82–1.17; P = .842).
HA-CDI occurred in 88 cases (1.2%) among this high-risk cohort.
Agreement with an ASP recommendation did not increase the
odds of acquiring HA-CDI (aOR, 01.59; 95% CI, 0.35–7.30;
P = .544).
Secondary outcomes
Of the 1,768 patients with 1 or more ASP recommendations, 831
(47.0%) had a single ASP review during their hospitalization.
Among these 831 patients, the LOS for agreement with ASP recommendations was significantly shorter compared to cases in
which disagreement occurred (10.2 days vs 12.5 days; P = .021)
(Fig. 2).
In total, 412 VAT cases were included in the comparison of ASP
recommendation with treatment failure and treatment duration.
Of these cases, 45 (11.0%) experienced treatment failure, thus
requiring reinitiation of antibiotic therapy within 14 days of completing their original treatment. The ASP recommended stopping
therapy in 99 cases (24.0%) and optimizing therapy in 65 cases
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Table 3. Adjusted Odds of Mortality, HA-CDI, and 30-Day Readmission
Died
(N=356)

HA-CDI
(N=88)

Readmitted
(N=2,608)

Variable

Adj OR (95% CI)

P Value

Adj OR (95% CI)

P Value

Adj OR (95% CI)

P Value

Any ASP recommendation

0.0.72 (0.54–0.96)

.023

0.84 (0.43–1.66)

.622

0.95 (0.83–1.08)

.408

Stop therapy

0.62 (0.42–0.93)

.019

1.02 (0.43–2.45)

.957

0.98 (0.82–1.17)

.842

Narrow therapy

0.69 (0.38–1.27)

.232

0.32 (0.04–2.40)

.268

1.01 (0.79–1.29)

.964

Agreed with recommendationsa

1.66 (0.88–3.10)

.113

1.59 (0.35–7.30)

.544

1.19 (0.89–1.59)

.231

Note. HA-CDI, hospital-acquired Clostridium difficile infection; ASP, antimicrobial stewardship program.
a
Among patients with ASP recommendations.

Fig. 1. Antimicrobial stewardship program recommendations by clinical service and rates of agreement.

Fig. 2. Hospital length of stay in high-risk children with a
single ASP review with recommendation.
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(15.8%). The medical team agreed with the ASP recommendation
in 60% of these cases. No statistically significant differences in VAT
treatment failure were observed when comparing any recommendation versus no recommendation (8.51% vs 13.00%; P = .157) or
agreement versus disagreement of an ASP recommendation
(10.58% vs 7.14%; P = .595). The mean duration of treatment
was 1.16 days shorter for VAT patients, with an agreed-upon stop
recommendation compared to VAT with no recommendation
(4.60 vs 5.76; P =.007). Those experiencing treatment failure
received a longer antimicrobial treatment course than those
patients without treatment failure (6.42 days vs 5.61 days; P =.033).
Discussion
Although ASPs are increasingly an integrated part of hospital care,
data on the impact of ASP on high-risk pediatric patients (eg, those
in the ICU or oncology ward) are limited. This study yielded
several important findings. First, ASP recommendations that
frequently included stop therapy in high-risk pediatric patients
did not result in worse clinical outcomes. Second, in patients with
a single ASP review during their hospitalization, agreement with an
ASP recommendation was associated with shorter LOS. And third,
ASP recommendations can result in shorter antibiotic durations
when treating common high-risk infections such as VAT without
an increase in the treatment failure rate.
Unique challenges and barriers are encountered by ASPs in
addressing appropriate use of antibiotics among ICU and oncology
patients.18,19 Broad-spectrum antimicrobial use is high, and prompt
initiation of appropriate antimicrobials is critical in these vulnerable
patients. Durations of antimicrobial therapy are often not clearly
defined in high-risk children. Underlying immunocompromised
conditions modify both the inflammatory response to infection
and the response to treatment.20 However, the undesired consequences of broad-spectrum antimicrobial use is also more frequent,
including infection with multidrug-resistant pathogens and HACDI.3,4,21,22 Thus, stewardship efforts are extremely important in
this population both to minimize the unnecessary use of antimicrobials and to optimize the antimicrobials being used.
Previously, we noted ~22% disagreement by our general pediatric
medical team with ASP recommendations at our hospital, compared
to 30% disagreement observed among the team treating this highrisk pediatric cohort.11 Hesitation by physicians to de-escalate or
stop antimicrobials because of disease severity, especially in highrisk patients, can be challenging for ASP teams.23 Thus, demonstrating that stewardship efforts, including the recommendation to stop
therapy, do not result in increased morbidity or mortality is important. A recent systematic review and meta-analysis of audit with
feedback in the ICU setting, using mortality as the outcome, did
not identify an increased risk of death with ASP prospective audit
with feedback.6 Our results corroborate previous reports in high-risk
populations that have shown that ASPs do not result in higher mortality or readmissions.6,23 Additionally in our study, patients with a
single ASP review and agreed upon recommendations had a shorter
LOS, which further highlights the potential benefits of the ASP.
Further collaboration with high-risk providers is critical to developing strategies for de-escalation and discontinuation of antimicrobials when detriment supersedes benefit for specific diagnoses. In this
study, agreement with ASP recommendations for VAT did not result
in more treatment failures nor did an extended course of antimicrobials protect against treatment failure. In fact, VAT patients who
experienced treatment failure actually had significantly longer durations of antimicrobial therapy. Previous research has demonstrated
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that a longer course of antibiotics for VAT is not clinically beneficial
and results in the acquisition of multidrug-resistant pathogens.24
Despite this finding, VAT remains a common diagnosis accounting
for nearly 20% of all cases for which ASP is intervening with limited
success. Recommendations to stop or modify antimicrobial therapy
for VAT treatment was disagreed upon 40% of the time.
The evaluation of clinical outcomes associated with ASP recommendations in high-risk pediatric patients is limited.
Demonstrating the impact of ASPs to high-risk patient providers
is important. Specifically, it is important to share the clinical
impact of modifying or stopping antimicrobial therapy in appropriate situations on these patients. Although the obstacles of stewardship in high-risk patients are clear, advances in diagnostics,
biomarkers, and new antimicrobials further iterates opportunities
for ASP in ICU and immunocompromised patients.25 Identifying
new strategies to enhance communication between ASP and highrisk providers is needed. Patel et al26 found that creation of a nonpunitive atmosphere when working with NICU teams and providing customized feedback was effective in enhancing ASP in the
neonatal setting. Coordinating ASP efforts with existing quality
initiatives may prove to be an efficient and effective strategy to
minimize redundancy with ongoing safety work.27
Our study has several limitations. Our results are limited to a
single center and thus may not be generalizable. The study was
retrospective in nature and cases of VAT were based on the medical provider’s clinical diagnosis of VAT rather than a strict clinical
definition.28 Thus, inclusion of cases that were not truly VAT may
have occurred. The approach used to define HA-CDI using both
test results and treatment for HA-CDI could have failed to detect
true cases; however, we did perform validation on 35 cases and
found our approach to have 100% sensitivity and specificity.
ASP recommendations and agreement were entered into an electronic data capture form manually, with potential for data entry
errors. However, given our large sample size, limited data entry
errors likely would not influence the results. Our high-risk
patients are heterogeneous given that we included hospitalized
children from the H/O ward, the NICU, and the PICU. We elected
to group all patients in this high-risk cohort given their overall
high use of antibiotic use and underlying case complexity.
Further studies to assess each group individually and to focus
on specific subpopulations such as cardiac ICU and bone marrow
transplant patients may provide further insight into specific unitbased ASP recommendations and outcomes and will contribute to
a better understanding of why disagreements between prescribers
and ASP occur.
In conclusion, the ASP recommendation for pediatric high-risk
patients in this study was frequently to stop antimicrobial therapy.
Medical providers disagreed with ASP recommendations in nearly
one-third of cases. However, when ASP recommendations were
made, patients did not have an increased likelihood of worse hospital outcomes. Further work is needed to enhance stewardship
efforts in high-risk pediatric patients, including further demonstrations of how ASPs can directly impact clinical outcomes.
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